A new chemo immunotherapy combination based on CD nanosponges against pancreatic cancer
Pancreatic cancer is resistant not only to chemotherapy but also to immunotherapy; therefore, identifying strategic alternatives is still necessary. Recently,
A forum for researchers, students and applicants in the field of cyclodextrin technology
Pancreatic cancer is resistant not only to chemotherapy but also to immunotherapy; therefore, identifying strategic alternatives is still necessary. Recently,
Pancreatic cancer (PC) is a highly lethal and aggressive malignancy, currently one of the leading causes of cancer-related deaths worldwide,
A novel β-cyclodextrin-aza[5]helicene conjugate as theranostic platform for anticancer agents delivery in cancer cells is reported. The carrier was synthesized